Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГНЦ социальной и судебной психиатрии им. В.П.Сербского, Москва
Список исп. литературыСкрыть список 1. Мосолов С.Н. Основы психофармакотерапии. М., 1996. 2. Смулевич А.В, Дробижев М.Ю., Иванов С.В. Транквилизаторы – производные бензодиазепина в психиатрии и общей медицине. М., 1999. 3. Чеберда О.А. Клинические особенности больных, длительно принимающих бензодиазепиновые транквилизаторы. Рос. психиатр. журн. 2006; 1: 70–5. 4. Ястребов Д.В. Симптоматика, ассоциированная с прекращением приема антидепрессантов. Механизмы развития, способы предотвращения и коррекции. Психиатр. и психофармакотер. 2011; 36: 14–20. 5. Ястребов Д.В. Алпразолам сегодня: 30 лет дискуссии об индивидуальных показаниях и безопасности. Психиатр. и психофармакотер. 2012; 1: 62–8. 6. Achmin J, Zarycranski W, Taylor KP et al. Effects of venlafaxine on the pharmacokinetics of alprazolam. Psychopharmacol Bull 1998; 34: 211–9. 7. Alexander PE. The need for extended-release medications. Curr Ther Res 1995; 56: 940–6. 8. Ballenger JC, Wheadon DE, Steiner M. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiat 1998; 155: 36–42. 9. Beitman BD, Basha I, Flaker G et al. Non-fearful panic disorder: panic attacks without fear. Behav Res Ther 1987; 25: 487–92. 10. Dämgen K, Lüddens H. Zaleplon displays a selectivity to recombinant GABAA receptors different from zolpidem, zopiclone and benzodiazepines. Neurosci Res Commun 1999; 25: 139–48. 11. Dehlin O, Kullingsjö H, Lidén A et al. Pharmacokinetics of alprazolam in geriatric patients with neurotic depression. Pharmacol Toxicol 1991; 68: 121–4. 12. Doble A. New insights into the mechanisms of action hypnotics. J Psychopharmacol 1999; 13 (Suppl. 4): s11–20. 13. Fawcett JA, Kravitz HM. Alprazolam: pharmacokinetics, clinical efficacy, and mechanism of action. Pharmacother 1982; 2: 243–54. 14. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994; 46: 35–9. 15. Furukawa TA, Streiner DL, Young LT. Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. J Affect Disord 2001; 65 (2): 173–7. 16. Furukori H, Otani K, Yasui N et al. Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. Neuropsychopharmacol 1998; 18: 364–9. 17. Greenblatt DJ, Wright E. Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin Pharmacokinet 1993; 24: 453–71. 18. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic vs psychic symptoms. J Clin Psychiat 1988; 49: 293–301. 19. Hollifield M, Katon W, Skipper B et al. Panic disorder and quality of life: variables predictive of functional impairment. Am J Psychiat 1997; 154: 766–72. 20. Kassam A, Patten SB. Hypnotic use in a population-based sample of over thirty-five thousand interviewed Canadians. Popul Health Metr 2006; 24 (4): 15. 21. Kessler RC, Chiu WT, Jin R et al. The epidemiology of panic attacks, panic disorder, and agoraphobia in the Na-tional Comorbidity Survey Replication. Arch Gen Psychiat 2006; 63: 415–24. 22. Lesser IM, Lydiard RB, Antal E et al. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiat 1992; 149: 1556–62. 23. Lydiard RB, Rickels K, Herman B, Feltner E. Pregabalin for psychic and somatic symptoms of GAD. Intern J Neuropsychopharmacol 2010; 13: 229–41. 24. Marks I. The classification of phobic disorders. British J Psy 1970; 116: 377–86. 25. Márquez M, Arenoso H, Caruso N. Efficacy of alprazolam sublingual tablets in the treatment of the acute phase of panic disorders. Actas Esp Psiquiat 2011; 39 (2): 88–94. 26. von Moltke L, Greenblatt DJ, Cotreau-Bibbo MM et al. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmac 1994; 38: 23–31. 27. Nash JR, Nutt DJ. Pharmacotherapy of anxiety. Hand Exp Pharmacol 2005; 169: 469–501. 28. Noyes R, Reich J, Clancy J, O\'Gorman TW. Reduction in hypochondriasis with treatment of panic disorder. Br J Psychiat 1986; 149: 631–5. 29. Noyes R, Du Pont RL, Pecknold JC et al. Alprazolam in panic disorder and agoraphobia: Patient acceptance, side effects, and safety. Arch Gen Psychiat 1988; 45: 423–8. 30. Pecknold JC, Swinson RP, Kuch K, Lewis CP. Alprazolam in panic disorder and agoraphobia: discontinuation effects. Arch Gen Psychiat 1988; 45: 429–36. 31. Petursson H, Lader M. Dependence on tranquilizers. Oxford University Press 1984. 32. Porcelli P, De Carne M. Non-fearful panic disorder in gastroenterology. Psychosomatics 2008; 49: 543–5. 33. Rickels K, Downing R, Schweizer E et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiat 1993; 50: 884–95. 34. Rief W, Martin A, Klaiberg A et al. Specific effects of depression, panic, and somatic symptoms on illness behavior. Psychosom Med 2005; 67: 596–601. 35. Rudolph U, Crestani F, Möhler H. GABA-A-receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 2001; 22: 188–94. 36. Russell JL, Kushner MG, Beitman BD, Bartels KM. Nonfearful panic disorder in neurology patients validated by lactate challenge. Am J Psychiat 1991; 148 (3): 361–4. 37. Sanger DJ, Benavides J, Perrault G et al. Recent developments in the behavioral pharmacology of benzodiazepine (o)-receptors: Evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 1994; 18: 355–72. 38. Stein MB, Roy Byrne PP, Craske MG et al. Functional impact and health utility of anxiety disorders in primary care outpatients. Med Care 2005; 43: 1164–70. 39. Verster JC, Volkerts ER. Clinical pharmacology, clinical efficacy, and behavioral toxicity of Alprazolam: a review of the literature. CNS Drug Rev 2004; 10 (1): 45–76.